Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jon Kuehler"'
Autor:
John M. Ketcham, Jacob Haling, Shilpi Khare, Vickie Bowcut, David M. Briere, Aaron C. Burns, Robin J. Gunn, Anthony Ivetac, Jon Kuehler, Svitlana Kulyk, Jade Laguer, J. David Lawson, Krystal Moya, Natalie Nguyen, Lisa Rahbaek, Barbara Saechao, Christopher R. Smith, Niranjan Sudhakar, Nicole C. Thomas, Laura Vegar, Darin Vanderpool, Xiaolun Wang, Larry Yan, Peter Olson, James G. Christensen, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:9678-9690
SOS1 is one of the major guanine nucleotide exchange factors that regulates the ability of KRAS to cycle through its "on" and "off" states. Disrupting the SOS1:KRAS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afe52dccfc91d77da8d18ff2be215969
https://doi.org/10.1021/acs.jmedchem.2c00741
https://doi.org/10.1021/acs.jmedchem.2c00741
Autor:
Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski, David M. Briere, Aaron C. Burns, James G. Christensen, Jeffery Clarine, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, Ronald Jean-Baptiste, John M. Ketcham, Masakazu Kobayashi, Jon Kuehler, Svitlana Kulyk, J. David Lawson, Krystal Moya, Peter Olson, Lisa Rahbaek, Nicole C. Thomas, Xiaolun Wang, Laura M. Waters, Matthew A. Marx
Publikováno v:
Journal of Medicinal Chemistry. 65:1749-1766
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6807ba018e034c41898a959b92d453dc
https://doi.org/10.1021/acs.jmedchem.1c01900
https://doi.org/10.1021/acs.jmedchem.1c01900
Autor:
Christopher R. Smith, Svitlana Kulyk, Misbha Ud Din Ahmad, Valentina Arkhipova, James G. Christensen, Robin J. Gunn, Anthony Ivetac, John M. Ketcham, Jon Kuehler, J. David Lawson, Nicole C. Thomas, Xiaolun Wang, Matthew A. Marx
Publikováno v:
RSC Medicinal Chemistry. 13:1549-1564
Herein we describe our approach to prioritize five fragment hits with the objective of answering three questions: could the binding potency be improved? Were the series chemically tractable? Could additional co-crystal structures be solved?
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8c927f9ba7684ab99a67e20faf2bf6f
https://doi.org/10.1039/d2md00163b
https://doi.org/10.1039/d2md00163b
Autor:
Christopher R. Smith, Ruth Aranda, James G. Christensen, Lars D. Engstrom, Robin J. Gunn, Anthony Ivetac, John M. Ketcham, Jon Kuehler, J. David Lawson, Matthew A. Marx, Peter Olson, Nicole C. Thomas, Xiaolun Wang, Laura M. Waters, Svitlana Kulyk
Publikováno v:
Bioorganicmedicinal chemistry. 71
MRTX1719 is an inhibitor of the PRMT5/MTA complex and recently entered clinical trials for the treatment of MTAP-deleted cancers. MRTX1719 is a class 3 atropisomeric compound that requires a chiral synthesis or a chiral separation step in its prepara
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50d8dc89ffc4b87f35f5c33212dddbbe
https://pubmed.ncbi.nlm.nih.gov/35926325
https://pubmed.ncbi.nlm.nih.gov/35926325
Autor:
Christopher R, Smith, Ruth, Aranda, Thomas P, Bobinski, David M, Briere, Aaron C, Burns, James G, Christensen, Jeffery, Clarine, Lars D, Engstrom, Robin J, Gunn, Anthony, Ivetac, Ronald, Jean-Baptiste, John M, Ketcham, Masakazu, Kobayashi, Jon, Kuehler, Svitlana, Kulyk, J David, Lawson, Krystal, Moya, Peter, Olson, Lisa, Rahbaek, Nicole C, Thomas, Xiaolun, Wang, Laura M, Waters, Matthew A, Marx
Publikováno v:
Journal of medicinal chemistry. 65(3)
The PRMT5•MTA complex has recently emerged as a new synthetically lethal drug target for the treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9d6afde10fb43fd4032bf2afa3ede5ca
https://pubmed.ncbi.nlm.nih.gov/35041419
https://pubmed.ncbi.nlm.nih.gov/35041419
Autor:
Christopher Ronald Smith, Ruth Aranda, James G. Christensen, Lars Engstrom, Robin J. Gunn, Anthony Ivetac, John M. Ketcham, Jon Kuehler, J. David Lawson, Matthew Arnold Marx, Peter Olson, Nicole C. Thomas, Xiaolun Wang, Laura M. Waters, Svitlana Kulyk
Publikováno v:
SSRN Electronic Journal.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::419ce1917645b9b46f152c08c6f86f59
https://doi.org/10.2139/ssrn.4133317
https://doi.org/10.2139/ssrn.4133317
Autor:
John M. Ketcham, David M. Briere, Aaron C. Burns, James G. Christensen, Robin J. Gunn, Jacob Haling, Anthony Ivetac, Shilpi Khare, Jon Kuehler, Svitlana Kulyk, Jade Laguer, John D. Lawson, Krystal Moya, Natalie Nguyen, Peter Olson, Lisa Rahbaek, Christopher R. Smith, Niranjan Sudhakar, Nicole C. Thomas, Darin Vanderpool, Xiaolun Wang, Matthew A. Marx
Publikováno v:
Cancer Research. 82:LB505-LB505
KRAS mutations are the most common activating mutations in human cancer that ultimately lead to hyperactivation of the MAPK pathway and uncontrolled growth. KRAS functions as a small GTPase that cycles through its GTP-loaded “on” state and its GD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::90876ca61e88494e7565b576662f0b19
https://doi.org/10.1158/1538-7445.am2022-lb505
https://doi.org/10.1158/1538-7445.am2022-lb505